These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24577239)

  • 21. Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.
    Heffernan KS; Kuvin JT; Sarnak MJ; Perrone RD; Miskulin DC; Rudym D; Chandra P; Karas RH; Menon V
    Nephrol Dial Transplant; 2011 Aug; 26(8):2515-21. PubMed ID: 21292815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
    BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure response to exercise in unaffected relatives of autosomal dominant polycystic kidney disease patients: an observational study.
    Yenigun EC; Turgut D; Cevher SK; Yucel C; Aypak C; Dede F
    Int Urol Nephrol; 2023 Sep; 55(9):2313-2319. PubMed ID: 36872421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease.
    Menon V; Rudym D; Chandra P; Miskulin D; Perrone R; Sarnak M
    Clin J Am Soc Nephrol; 2011 Jan; 6(1):7-13. PubMed ID: 20829421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma asymmetric dimethylarginine (ADMA), nitrate and the indices of low-density lipoprotein oxidation.
    Päivä H; Laakso J; Ruokonen I; Luomala M; Saarela M; Solakivi T; Metso S; Nikkilä M; Wuolijoki E; Laaksonen R; Lehtimäki T
    Clin Chim Acta; 2006 Sep; 371(1-2):97-101. PubMed ID: 16626676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
    Demirel F; Bideci A; Cinaz P; Camurdan MO; Biberoğlu G; Yesilkaya E; Hasanoğlu A
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):129-34. PubMed ID: 17465999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease.
    Theodorakopoulou M; Raptis V; Loutradis C; Sarafidis P
    Semin Nephrol; 2019 Nov; 39(6):599-612. PubMed ID: 31836042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
    Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
    Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
    Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
    J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism.
    Ozcan O; Cakir E; Yaman H; Akgul EO; Erturk K; Beyhan Z; Bilgi C; Erbil MK
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):203-6. PubMed ID: 16060915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.
    Nowak KL; Gitomer B; Farmer-Bailey H; Wang W; Malaczewski M; Klawitter J; You Z; George D; Patel N; Jovanovich A; Chonchol M
    Am J Kidney Dis; 2019 Aug; 74(2):213-223. PubMed ID: 30803706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Copeptin levels and kidney function in ADPKD: case-control study.
    Corradi V; Martino F; Gastaldon F; Scalzotto E; Caprara C; Fortunato A; Pinaffo G; Marchetti C; Fabbi F; Giavarina D; Ferrari F; Rosner MH; Ronco C
    Clin Nephrol; 2016 Sep; 86(9):147-53. PubMed ID: 27487355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients.
    Fujii H; Takiuchi S; Kawano Y; Fukagawa M
    Am J Hypertens; 2008 Jun; 21(6):650-6. PubMed ID: 18443575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function.
    Marrocos MS; Teixeira AA; Quinto BM; Carmona Sde M; Kuniyoshi M; Rodrigues CJ; Dalboni MA; Manfredi S; Canziani ME; Batista MC
    Lipids Health Dis; 2016 Jan; 15():14. PubMed ID: 26790728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of OSR-1 With Vascular Dysfunction and Hypertension in Polycystic Kidney Disease.
    Kocyigit I; Taheri S; Eroglu E; Zararsiz G; Sener EF; Uzun I; Imamoglu H; Mehmetbeyoglu E; Unal A; Korkmaz K; Sipahioglu MH; Oymak O; Tokgoz B
    Ther Apher Dial; 2020 Feb; 24(1):64-71. PubMed ID: 31020807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients.
    Ebinç FA; Erten Y; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Mutluay R; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(4):401-6. PubMed ID: 18569913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.